{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:27:44Z","timestamp":1781825264978,"version":"3.54.5"},"reference-count":43,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Background: Physiologically based pharmacokinetic (PBPK) modeling is applied to address clinical pharmacology issues including dose selection and exposure assessments for special populations (e.g., pediatrics, and renally or hepatically impaired patients). The objective of this study was to evaluate the predictive performance of a PBPK model for dosing assessment of intravenous immunoglobulin (IVIG) and anti-D immunoglobulin (anti-D Ig) products in pregnant women. Methods: A minimal PBPK (mPBPK) model that incorporates pregnancy-specific physiological parameters and allometric scaling approaches was developed and evaluated for predicting the exposure of IVIG and anti-D Ig in pregnant women. The concentration versus time data were obtained from the published literature. Results: The IVIG (n = 22) and anti-D Ig (n = 29) concentrations were predicted using the mPBPK model with an average fold error of 1.17 and 1.22, respectively. A total of 100% and 95% of IVIG concentrations were predicted within the 0.5\u20132-fold and 0.5\u20131.5-fold prediction error ranges, respectively. For anti-D Ig, predictions fell within the 0.5\u20132-fold and 0.5\u20131.5-fold ranges for 93% and 76% concentrations, respectively. A mPBPK model-based simulation following administration of 0.5 g\/kg IVIG in 100 virtual nonpregnant and pregnant subjects revealed that the maximum plasma concentration (Cmax) was 15% lower and trough concentration (Ctrough) was 8% lower during the third trimester of pregnancy compared to nonpregnant subjects. In contrast, with flat dosing, Cmax and Ctrough were 32% and 26% lower in pregnant subjects, respectively. Overall, the model demonstrated reasonable predictive performance, and bodyweight-based dosing regimen is an acceptable approach that results in minimal change in exposure of IVIG in pregnant women.<\/jats:p>","DOI":"10.3390\/antib14040099","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:03:15Z","timestamp":1763564595000},"page":"99","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Physiologically Based Pharmacokinetic Model for Prediction of Immunoglobulins Exposure in Pregnant Women"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-6574","authenticated-orcid":false,"given":"Million A.","family":"Tegenge","sequence":"first","affiliation":[{"name":"Office of Biostatistics and Pharmacovigilance (OBPV), Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD 20993-0002, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2249.2009.04024.x","article-title":"Clinical applications of intravenous immunoglobulins (IVIg)\u2014beyond immunodeficiencies and neurology","volume":"158","author":"Hartung","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/cei.12485","article-title":"Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease","volume":"179","author":"Jolles","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Mahmood, I., Tegenge, M.A., and Golding, B. (2020). Considerations for Optimizing Dosing of Immunoglobulins Based on Pharmacokinetic Evidence. Antibodies, 9.","DOI":"10.3390\/antib9020024"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1542\/neo.22-1-e7","article-title":"Update on the Use of Intravenous Immunoglobulin in Pregnancy","volume":"22","author":"Hsu","year":"2021","journal-title":"NeoReviews"},{"key":"ref_5","unstructured":"(2022, March 21). FDA Package Insert: WinRho\u00ae SDF [Rho(D) Immune Globulin Intravenous (Human)], Available online: https:\/\/www.fda.gov\/media\/77860\/download."},{"key":"ref_6","unstructured":"(2022, March 21). FDA Package Insert: Rh0 (D) Immune Globulin Intravenous (Human) (Rhophylac), Available online: https:\/\/www.fda.gov\/media\/75013\/download."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/hae.13767","article-title":"Clinical Pharmacology Review of Plasma-derived and Recombinant Protein Products: CBER Experience and Perspectives on Model-Informed Drug Development","volume":"25","author":"Tegenge","year":"2019","journal-title":"Haemophilia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1592\/phco.26.6.813","article-title":"Pharmacokinetics of intravenous immunoglobulin: A systematic review","volume":"26","author":"Koleba","year":"2006","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kerr, J., Quinti, I., Eibl, M., Chapel, H., Spath, P.J., Sewell, W.A., Salama, A., van Schaik, I.N., Kuijpers, T.W., and Peter, H.H. (2014). Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe. Front. Immunol., 5.","DOI":"10.3389\/fimmu.2014.00629"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1600-0897.1996.tb00172.x","article-title":"Evolution of maternofetal transport of immunoglobulins during human pregnancy","volume":"36","author":"Malek","year":"1996","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0022-3476(86)80132-9","article-title":"Transplacental passage of intravenous immunoglobulin in the last trimester of pregnancy","volume":"109","author":"Sidiropoulos","year":"1986","journal-title":"J. Pediatr."},{"key":"ref_12","first-page":"77","article-title":"Immunoglobulin G binding sites on the human foetal intestine: A possible mechanism for the passive transfer of immunity from mother to infant","volume":"79","author":"Israel","year":"1993","journal-title":"Immunology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e12972","DOI":"10.1111\/aji.12972","article-title":"Expression of FcRn receptor in placental tissue and its relationship with IgG levels in term and preterm newborns","volume":"80","author":"Lozano","year":"2018","journal-title":"Am. J. Reprod. Immunol."},{"key":"ref_14","first-page":"303","article-title":"The placental transfer of IgG subclasses in human pregnancy","volume":"41","author":"Hindocha","year":"1980","journal-title":"Clin. Exp. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1002\/jcph.1848","article-title":"Model-Informed Drug Development in Pediatric Dose Selection","volume":"61","author":"Bi","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1002\/jcph.1853","article-title":"Methods Used for Pediatric Dose Selection in Drug Development Programs Submitted to the US FDA 2012-2020","volume":"61","author":"Green","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1002\/jcph.1863","article-title":"The European Medicines Agency Experience With Pediatric Dose Selection","volume":"61","author":"Manolis","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","article-title":"Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women","volume":"80","author":"Hirt","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"George, B., Lumen, A., Nguyen, C., Wesley, B., Wang, J., Beitz, J., and Crentsil, V. (2020). Application of physiologically based pharmacokinetic modeling for sertraline dosing recommendations in pregnancy. npj Syst. Biol. Appl., 6.","DOI":"10.1038\/s41540-020-00157-3"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/psp.2012.2","article-title":"A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: Verification and discerning the site of CYP3A induction","volume":"1","author":"Ke","year":"2012","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1208\/s12248-013-9505-3","article-title":"A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy","volume":"15","author":"Xia","year":"2013","journal-title":"AAPS J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/cpt.1084","article-title":"Physiologically based pharmacokinetic modeling in pregnancy: A systematic review of published models","volume":"104","author":"Dallmann","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/bcp.12207","article-title":"Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19","volume":"77","author":"Ke","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency","volume":"26","author":"Church","year":"2006","journal-title":"J. Clin. Immunol."},{"key":"ref_25","first-page":"39","article-title":"Pharmacokinetics of anti-D IgG in pregnant RhD-negative women","volume":"110","author":"Bichler","year":"2003","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1093\/humrep\/der227","article-title":"A two-center study on the pharmacokinetics of intravenous immunoglobulin before and during pregnancy in healthy women with poor obstetrical histories","volume":"26","author":"Ensom","year":"2011","journal-title":"Hum. Reprod."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1600-0412.2012.01377.x","article-title":"Pharmacokinetics of 250 \u03bcg anti-D IgG in the third trimester of pregnancy: An observational study","volume":"91","author":"Tiblad","year":"2012","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1471-0528.2005.00789.x","article-title":"General obstetrics: The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin","volume":"113","author":"MacKenzie","year":"2006","journal-title":"BJOG Int. J. Obstet. Gynaecol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10928-013-9332-2","article-title":"Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies","volume":"40","author":"Cao","year":"2013","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.clp.2019.02.014","article-title":"Principles of pharmacokinetics in the pregnant woman and fetus","volume":"46","author":"Ward","year":"2019","journal-title":"Clin. Perinatol."},{"key":"ref_31","first-page":"19","article-title":"Serum immunoglobulin (IgG, IgM, IgA) and IgG subclass concentrations in healthy children: A study using nephelometric technique","volume":"48","author":"Aksu","year":"2006","journal-title":"Turk. J. Pediatr."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(72)90926-9","article-title":"Uptake of IgG after intramuscular and subcutaneous injection","volume":"299","author":"Smith","year":"1972","journal-title":"Lancet"},{"key":"ref_33","unstructured":"(2021, November 10). NHANES 2011-2014 Adult Data. Available online: https:\/\/www.openlab.psu.edu\/nhanes\/."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2165\/11597440-000000000-00000","article-title":"Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy","volume":"51","author":"Abduljalil","year":"2012","journal-title":"Clin. Pharmacokinet."},{"key":"ref_35","unstructured":"FDA (2022, March 22). Guidance for Industry: Pharmacokinetics in Pregnancy\u2014Study Design, Data Analysis, and Impact on Dosing and Labeling, Available online: https:\/\/www.fda.gov\/media\/71353\/download."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10928-012-9280-2","article-title":"Applications of minimal physiologically-based pharmacokinetic models","volume":"39","author":"Cao","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1007\/s11095-015-1703-5","article-title":"Across-Species Scaling of Monoclonal Antibody Pharmacokinetics Using a Minimal PBPK Model","volume":"32","author":"Zhao","year":"2015","journal-title":"Pharm. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1002\/jcph.1846","article-title":"Spreadsheet-Based Minimal Physiological Models for the Prediction of Clearance of Therapeutic Proteins in Pediatric Patients","volume":"61","author":"Mahmood","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_39","unstructured":"(2025, February 11). ICH Harmonised Guideline General Principles for Model-Informed Drug Development M15; Draft Version. Available online: https:\/\/database.ich.org\/sites\/default\/files\/ICH_M15_EWG_Step2_DraftGuideline_2024_1031.pdf."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/A:1026194618660","article-title":"Reduction and lumping of physiologically based pharmacokinetic models: Prediction of the disposition of fentanyl and pethidine in humans by successively simplified models","volume":"30","author":"Bjorkman","year":"2003","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_41","first-page":"1144","article-title":"Effects of the FcRn developmental pharmacology on the pharmacokinetics of therapeutic monoclonal IgG antibody in pediatric subjects using minimal physiologically-based pharmacokinetic modelling","volume":"10","author":"Hardiansyah","year":"2018","journal-title":"MAbs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/jps.10345","article-title":"Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man","volume":"92","author":"Levy","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40268-019-0268-x","article-title":"Towards a Generic Tool for Prediction of Meropenem Systemic and Infection-Site Exposure: A Physiologically Based Pharmacokinetic Model for Adult Patients with Pneumonia","volume":"19","author":"Themans","year":"2019","journal-title":"Drugs R D"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/4\/99\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:12:58Z","timestamp":1763565178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/14\/4\/99"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["antib14040099"],"URL":"https:\/\/doi.org\/10.3390\/antib14040099","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}